Abstract: Disclosed herein are vesicular formulations comprising one or more phospholipids and one or more nonionic surfactants that are effective in the treatment of pain or inflammation or osteoarthritis, more specifically in the treatment of deep tissue pain, for example osteoarthritis and other joint or muscle pain, as well as methods of treating pain or inflammation or osteoarthritis, more specifically in the treatment of deep tissue pain, for example osteoarthritis and other joint or muscle pain using same.

Abstract: A pH-modified luminescent composition and methods. In composition, a marker exhibiting luminescence change over a indicatory period. pH-based luminesce change may be in intensity or in wavelength. One embodiment provides a luminescent composition, including a selected luminescent marker having a first phase; and a selected ionizing agent comprising a second phase. The selected luminescent marker exhibits luminescence for an indicatory period responsive to intermixing of the first phase with the second phase. A selected antimicrobial agent combined with the first phase of the luminescent composition, wherein intermixing of the first phase with the second phase is at least a portion of a hand hygiene protocol.

Abstract: Suggested are biocide compositions, comprising (a) esters based on ketocarboxylic acids, (b) biocides, and optionally (c) oil components or co-solvents and/or (d) emulsifiers. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. over a longer period.

Abstract: In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient; an ester; a non-ionic surfactant; a polar solvent; water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster.

Abstract: Formulations of personal care compositions and personal care concentrate compositions containing salts of sulfonated fatty acid esters and/or salts of sulfonated fatty acids, and an alkyl betaine or sultaine are described. Personal care compositions of the present technology include liquid hand soaps, bath and shower washes, shampoos, 2-in-1 or 3-in-1 shampoos, antidandruff shampoo, facial cleaners, among others.

Abstract: A biocompatible putty formulation suitable for insertion within chronic and acute wounds of humans and animals, the formulation containing a topical antibiotic, a biocompatible humectant, a biocompatible viscosity-building agent, and at least 5% water, by weight, the humectant and the viscosity-building agent intimately mixed within the formulation, the formulation adapted whereby the formulation remains a solid over the entire temperature range of 20° C. to 35° C.

Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, —savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

Abstract: A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.

Abstract: A carrier composition of the present invention comprises a phosphate compound of an electron transfer agent and a relatively high concentration of a polar protic solvent. A biologically active compound may be formulated with a carrier composition of the present invention to provide a formulation.

Abstract: The invention relates to a cosmetic composition having a cooling effect, particularly a clear gel or a spray. The composition has a long-lasting cooling effect of about 8 hours and comprises a cooling complex consisting of 0.05-0.15% Menthyl Lactate, 0.1-0.2% Menthyl PCA and 0.05-0.2% Ethyl Menthane Carboxamide.

Abstract: The present invention relates to some perfuming ingredients which are esters of formula (I) wherein R1 and R2 represent each a hydrogen atom or a methyl or ethyl group; and R3 represents a C5-C8 group of formula satured or unsatured linear, branched or cyclic group.

Abstract: A liquid crystal composition contains liquid crystals containing one kind of or two or more kinds of silicone surfactants, a phenyl-modified silicone oil and water. The liquid crystal composition of the present invention contains 5 to 95% by weight in total of one kind of or two or more kinds of silicone surfactants, 0.1 to 90% by weight of a phenyl-modified silicone oil and 0.1 to 90% by weight of water. The liquid crystal composition of the present invention can solubilize hydrophobic compounds having poor solubility (for example, hydrocarbon oils such as squalane, fatty acids such as oleic acid and lipoic acid and ester oils such as cetyl isooctanoate) and is thus useful, for example, as toiletry materials and cosmetic materials.

Abstract: A composition comprising at least one ?-cyanodiphenylacrylate and at least oxyalkylenated organosiloxane emulsifier, and a method for stabilizing a composition by formulating with at least one ?-cyanodiphenylacrylate and at least one oxyalkylenated organosiloxane emulsifier.

Abstract: Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a biodegradable liquid polymer implant are provided.

Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Abstract: The present invention relates to processes for the preparation of a flavoring concentrate, to a flavoring concentrate which can be prepared by a process according to the invention, to products comprising one or more flavoring concentrates according to the invention, and to processes for the concentration of flavoring and/or aromatic substances.

Abstract: The present invention discloses systems and methods for controlling arthropod populations. The systems include a polymeric substrate, a semiochemical that is reactive upon an adult-stage arthropod, and an insecticide that is toxic to an immature-stage arthropod. The semiochemical may be a sex pheromone that disrupts mating behavior of the adult-stage arthropod. The insecticide may be a per os insecticide that only affects the immature-stage arthropod. The arthropod to be controlled may be gypsy moths, in which case the semiochemical may be disparlure and the insecticide may be spinosad. Further disclosed are methods for preparing systems for use in controlling arthropod populations.

Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Abstract: The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.

Abstract: An isotropic or homogeneous emulsion system comprises an oil phase including fat esters of illipe fat and a solubilizer; a non-ionic surfactants; and deionized water; characterized in that the solubilizer is a mixture of polyethyleneglycol-40 hydrogenated castor oil, polysorbate 20 and octoxynol-12.

Abstract: The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

Abstract: Problem: To provide a technique of simply and easily convert a powder makeup cosmetic such as powdery foundation or the like into a pickering-emulsificated liquid makeup cosmetic such as liquid foundation or the like. Means for Resolution: A solvent composition for use as a dispersion medium for converting a powder makeup cosmetic into a pickering-emulsificated liquid makeup cosmetic, which comprises (a) from 0.1 to 65% by mass of an aqueous component, and (b) from 35 to 99.9% by mass of one or more oily components selected from hydrocarbon oils and silicone oils.

Abstract: A cosmetic material includes a component selected from diethyl amino hydroxy benzoyl hexyl benzoate and/or 4-tert-buthyl-4?-methoxy dibenzoyl methane as a component that crystallizes and precipitates easily and blends, as a dissolution stabilizer of the component, one or more types of octyl hydroxy stearate oligomer selected from a dimer to heptamer of octyl hydroxy stearate, whereby precipitation of UV absorbents and other poorly soluble components can be prevented over a long period.

Abstract: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

Abstract: A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing ?-ethylhexyl ?-cyano-?-(4-methoxyphenyl)-?-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4?-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage of the skin upon exposure to sunlight or other sources of light in the ultraviolet (UV), visible, and infrared (IR) ranges.

Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).

Abstract: A water in oil emulsion lip treatment composition comprising at least one non-polar silicone oil, at least one non-polar organic oil, at least one amphiphilic organic emollient oil, at least one water in oil surfactant; and at least one oil in water surfactant.

Abstract: Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.

Abstract: A fatty acid ester of pentaerythritol, a pentaerythritol oligomer, or mixtures thereof, where the fatty acid has 6 to 22 carbon atoms, and the ester contains less than 0.3% by weight C17 fatty acid acyl groups and has a melting point of at least 30° C. is provided. A process for the production of a C16/C18 fatty acid pentaerythritol ester including (A) providing about 1.8 to about 2.2 mol of a fatty acid mixture per mol of pentaerythritol; (B) esterifying component (A) at temperatures ranging from about 180° C. to about 250° C. in an inert gas atmosphere in the absence of solvent to form a reaction mixture; (C) stirring the reaction mixture in vacuo until it has an acid value of less than 1 and an OH value of 145 to 158 is provided. A cosmetic and/or pharmaceutical composition including the above-described ester is also provided.

Abstract: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their pay-load upon exposure to acoustic energy.

Abstract: The present invention comprises a compound of a compound of Formula 1 wherein Rf is a C2 to C12 perfluoroalkyl optionally interrupted by one to four moieties each independently selected from the group consisting of —CH2—, —O—, —S—, —S(O)—, and —S(O)2—; n is 1 to 6; m is 0 to 2, provided that m is less than or equal to n. X and Y are each independently O or NR, R is hydrogen or C1 to C6 alkyl; R1, and R2 are each independently C1 to C6 alkyl, optionally containing one or more oxygen atoms and may form a ring selected from the group of piperidine, pyrrolidine, and morpholine; and R3 is O?, (CH2)pC(O)O?, (CH2)pCH(OH)(CH2)SO3?, and (CH2)qSO3?; p is 1 to 4; and q is 2 to 4 which is useful as a surfactant.

Abstract: A lotion composition is provided. The lotion composition can comprise a) about 0.1% to about 90%, by weight, of a microcrystalline wax; b) about 0.1% to about 25%, by weight, of POE-4 monolaurate; c) about 0.1% to about 50%, by weight, of POE-8 monostearate; and d) a carrier.

Abstract: Described are agrochemical compositions comprising alkoxylation products according to general formula (I) R1(CO)m—O—[R2O]nR3??(I) wherein R1 is a linear or branched, saturated or unsaturated, optionally hydroxy-functionalised hydrocarbyl radical containing 8 to 30 carbon atoms, R2 is an ethylene, propylene or butylene group or mixtures thereof, R3 is hydrogen or an acyl group containing 1 to 8 carbon atoms, m is 0 or 1, n is an integer between 3 and 100. When R3 is an acyl group, R2 is ethylene, propylene or mixtures thereof, and when R3 is hydrogen, R2 is ethylene, propylene, butylene or mixtures thereof provided that the terminal group represents a butylene oxide unit.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.

Abstract: A gelator made of an aliphatic oxyglycyl polyol that is capable of forming a gel by a small amount of addition in a pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility and biodegradability. A gelator including an aliphatic oxyglycyl polyol of Formula (1) wherein R is a C18-20 saturated aliphatic group or a C18-20 unsaturated aliphatic group having one double bond) or a pharmaceutically usable salt thereof; a self-assembly formed by self-assembling of the gelator; and a gel comprising the gelator or the self-assembly, and water, an alcohol, an aqueous solution, an alcohol solution, a hydrophilic organic solution, or a hydrophobic organic solution.

Abstract: The present invention relates to compositions comprising a structured benefit agent pre-mix or delivery vehicle comprising benefit agent structured with crystalline materials, as defined, which when separately prepared and combined after preparation, provides enhanced delivery of benefit agent from a personal product bar carrying composition into which the premix is added. The use of structured benefit agent also enhances delivery of separate benefit agents in the premix (which may or may not be structured) and of separate benefit agents added separately from the premix.

Abstract: The invention relates to esters of general formula (I) R1—C(?O)—O—R2, wherein (1) R1 represents a linear alkyl radical having 7 to 9 carbon atoms and R2 represents a linear alkyl radical having 9 to 10 carbon atoms or (2) R1 is a linear alkyl radical having 8 to 9 carbon atoms and R2 is a linear alkyl radical having 8 carbon atoms, or (3) R1 is a linear alkyl radical having 7 to 9 carbon atoms and R2 is a linear alkyl radical having 7 carbon atoms, or (4) R1 is an alkyl radical having 7 or 8 carbon atoms and R2 is an alkyl radical having 9 carbon atoms where, if R1 is a linear alkyl radical, R2 is a branched alkyl radical, or, if R1 is a branched alkyl radical, R2 is a linear alkyl radical or (5) R1 represents an alkyl radical having 8 carbon atoms and R2 is an alkyl radical having 8 carbon atoms, where, if R1 is a linear alkyl radical, R2 is a branched alkyl radical, or, if R1 is a branched alkyl radical, R2 is a linear alkyl radical, or n-octyl isooctanoate, n-dec I isooctanoate, n-decyl isononanoate, isono

Abstract: A transmembrane penetration enhancer includes a thermotropic liquid crystal suitably prepared for use in a therapeutic system to improve delivery of at least one active ingredient across a biomembrane and/or skin. The thermotropic liquid crystal comprises at least one cholesteryl ester and is effective in a mesomorphic state at a temperature of the biomembrane and/or skin. A therapeutic system includes the prepared thermotropic liquid crystal for enahanced transmembrane penetration and at least one active ingredient for delivery by the thermotropic liquid crystal. A method for making and using the transmembrane penetration enhancer is presented.

Abstract: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.

Abstract: Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules.

Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and paraben, and are substantially free of paraben crystalline particles after an extended period of storage.

Abstract: The present invention relates to compounds of formula I and II, which are functionalized amino acids, and polymers formed from the same. Polymers formed from the functionalized amino acids are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.

Abstract: The invention is directed to a mixture of esters according to the general formula (I), R1—C(?O)—O—R2, wherein R1 is an alkyl moiety with 7 to 9 carbon atoms and wherein R2 is a an alkyl moiety with 8 to 10 carbon atoms, wherein the mixture comprises 5 to 60 weight-% of ester of the general formula (I), wherein R1 is an alkyl moiety with 9 carbon atoms, based on the total amount of esters according to formula (I) and/or wherein the mixture comprises 5 to 60 weight-% of ester of the general formula (I), wherein R2 is an alkyl moiety with 10 carbon atoms, based on the total amount of esters according to formula (I). The invention is further directed to cosmetic and/or pharmaceutical compositions comprising such esters and processes for the production of such esters.

Abstract: This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.

Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Abstract: The present invention relates to novel compounds and their use in fragrance compositions. Novel 3.2.1-bicyclo-octene and -octane compounds of the present invention are represented by formula: wherein R is selected from the group consisting of hydrogen, acetate, carbonate monomethyl ester, and allyloxy; and wherein the broken line represents a single or double bond.

Abstract: The method disclosed herein comprises using a non-polar alkane in the continuous phase of an emulsion process to aid in the removal of dispersed phase solvent from the microparticles. The microparticles can further be subjected to a post-production treatment process, involving a non-polar alkane suspension and a rinse, to further reduce residual dispersed phase solvent levels.

Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.

Abstract: A formulation delivery system is disclosed. When configured as a pro-liposome oral tablet, the tablet comprises a blend of at least one Iiposome forming ingredient, at least one active ingredient and at least one co-disintegrant. After ingestion at least a portion of the tablet disintegrates in a portion of an alimentary system to provide one or more in situ Iiposome encapsulated active ingredients. A method of producing the pro-liposome oral tablet and a method of therapeutically dosing with the pro-liposome oral tablet are further disclosed. The formulation delivery system may be configured as any one of a pro-liposome oral tablet, sublingual tablet, caplet, capsule and aerosol.